We have analysed haplotypes for four DNA polymorphisms, closely linked to the cystic fibrosis (CF) gene, in 82 Spanish families, in which the CF probands are either homozygous for non-AF508 mutations or heterozygous for the AF508 deletion and other CF mutations. The analysis provides genetic data for a new polymorphism for the closely linked marker pKM.19, which is very strongly associated with CF. Haplotypes generated with the four marker loci are also in strong disequilibrium with the non-AF508 CF chromosomes. The data reported here are useful in 1 in 4 risk pregnancies of parents who have no living affected child, and when counselling close relatives of CF families who are negative for the major CF mutation. The data presented are useful in our population, in which the majority of CF mutations, apart from the AF508 deletion, are uncommon. For other populations in which mutation heterogeneity is also very high, it still might be more feasible to use RFLPs for diagnostic purposes, when analysis for common mutations is negative and DNA is available from the index patient. The experience presented here provides a model for these population groups who in turn should obtain their own haplotype data. In addition, the model system for genetic counselling presented here might also be useful for other genetic disorders.
Genetic testing for cystic fibrosis (CF) has been considerably improved since the isolation of the CF gene and the discovery of the major CF mutation, which consists of a three nucleotide deletion (AF508) in the first putative ATP binding domain of the predicted protein (CF transmembrane conductance regulator, CFTR). '-3 The AF508 deletion has been found in approximately 70% of North American34 and north European5 CF chromosomes, but in only 50% of south Europeans.67 Although several other mutations have been identified (CF Genetic Consortium), most of them are very uncommon,°0 and others have a frequency of approximately 3-5% in North Americans and north Europeans, but they seem to be even rarer in other populations. 8 Haplotype analysis of CF chromosomes based on DNA markers closely linked to the disease locus suggests that the remainder of the CF mutant allele pool (non-A&F508 mutations) in the Spanish population consists of various distinct mutations.31' Mutation analysis provides, at the moment, full informativeness for prenatal diagnosis in only 25% (south European) to 55% (north European and North American) of couples.412 Therefore, prenatal diagnosis and carrier detection of CF is currently performed by the analysis of the AF508 deletion or other defined mutations, and by using closely linked markers detecting RFLPs.41 As the non-AF508 CF mutant allele pool is so heterogeneous, it may be more useful to use closely linked markers for genetic diagnosis of CF, when mutation analysis is negative for the common mutations.
We present here the haplotype analysis of AF508, non-AF508 CF chromosomes, and normal chromosomes, in CF families of Spanish origin, with four RFLPs closely linked to CF. A new RFLP analysed, pKM.19/ScrfI,3 shows the highest non-random allelic association with CF (in both AF508 and non-AF508 CF chromosomes) described so far. The association between several haplotypes and non-AF508 chromosomes might be used to improve genetic analysis when DNA is not available from the CF proband and when counselling close relatives of CF families negative for common CF mutations. '4 Materials and methods DNA analysis was performed on a large series of families with members affected with CF. The families were referred to our centre in Barcelona between 1986 and 1989 from most of the regions of the country, and all were of Spanish origin. Diagnosis was confirmed by both the typical symptoms and two positive sweat tests. Only the families in which the CF patients were either homozygous for non-AF508 mutations or heterozygous for the AF508 deletion and other unknown CF mutations (in total 82 families) were considered for the present analysis.,, Genomic DNA from blood containing EDTA as anticoagulant was extracted from the parents, the CF patient, and in some cases from the grandparents. DNA was subjected to amplification as recommended by the manufacturer of Taq polymerase. Each 100 il reaction mixture contained 50 mmol/l potassium chloride, 10 mmol/l Tris-hydrochloric acid (pH 7-8), 1-5 mmol/l magnesium chloride, 200 imol/I of each deoxynucleotide triphosphate, 30 pmol/l of each oligonucleotide primer, 300 ng of genomic DNA, and 2-0 units of Taq polymerase; 50 p1 of mineral oil was added to each reaction.
We studied four polymorphic loci: pXV-2c/TaqI, pKM. 19/ScrfI, pKM.19/PstI, and pMP6d-9/MspI. The loci were analysed by restriction enzyme digestion after PCR amplification with the pairs of primers previously described '5'8 and j, the probabilities of being CF chromosomes are increased to 1 in 13-3, 1 in 35 5, 1 in 82-6, and 1 in 52-6, respectively. Thus, the probability of a haplotype derived from a parent with no family history of CF and not carrying the AF508 mutation can be ascertained using these data. The probability that a phenotypically normal subject with genotype ab is a carrier of a non-AF508 mutation can be calculated as follows: (Fb F;) where Fb and F' are the frequencies of haplotype b in their respective non-AF508 and normal chromosome populations. Table 3 shows the probabilities of carrying a non-AF508 mutation for all 66 expected genotypes of phenotypically normal subjects in the Spanish population. Considering a carrier frequency for a non-AF508 mutation of 1 in 50, this figure is notably improved for some genotypes (for example, for genotypes df 1 in 155 and dh 1 in 256-4). For other genotypes the probabilities of being a carrier are considerably increased (aa 1 in 7-2, ab 1 in 10 1, and ad 1 in 13-3). Other genotypes only show slight modifications of the previous carrier risk figures. The typical situation in which haplotype information could improve the carrier risk figure is for couples with less than a 1 in 4 risk of CF (for example, couples consisting of a known carrier and a person from the general population), where the low risk parent does not have the AF508 mutation. The risk of the partner being a carrier is modified from 1 in 25 to 1 in 50 after mutation analysis. Haplotype analysis including the pKM. 19/ScrfI marker allows the modification of their risk of being a carrier for a non-AF508 mutation. A final carrier risk could be given, which ranges from 1 in 7-2 to 1 in 256-4, and for some genotypes it is practically zero. Thus, for the couple, the risk of having a CF child, calculated by mutation analysis is 1 in 200, whereas using haplotype analysis the risk can be further modified to between 1 in 28-8 and 1 in 825-6, and in some cases to practically zero.
HAPLOTYPE ANALYSIS IN COUPLES WITH A 1 IN 4 RISK OF CF
When counselling parents of a dead child for a further pregnancy, the probabilities for CF of each possible genotype in the fetus are calculated from haplotype data in the parents using Bayes's theorem. The calculations are performed for each possible phase in each parent, under the assumption that both parents are obligate carriers of a CF mutation. Considering one parent with genotype ab, the probabilities that the CF mutation is associated either with haplotype a or with haplotype b, given the parent is ab, are:
Considering that the other parent has a genotype cd, then the probabilities that the CF mutation is associated either with c or d are: P(CF¢\cd) or P(CFd\cd) = 1-P(CF.\cd).
The probabilities for each possible genotype are the products of the probabilities that each haplotype contributed by each parent carries a CF mutation: P(CF.c\ab and cd in parents) = P(CF.\ab) x P(CF,\cd) P(CFb.\ab and cd in parents) = P(CFb\ab) x P(CF,\cd) P(CFad\ab and cd in parents) = P(CFa\ab) x P(CFd\cd) P(CFbd\ab and cd in parents) = P(CFb\ab) x P(CFd\cd).
These calculations can also be used in the case where one of the parents carries a known mutation (for example, AF508 associated with haplotype a) and that this mutation is present in the fetal genotype. In this case, the probability of the fetus being CF is equal to the probability that the haplotype contributed by the parent carries a non-AF508 mutation: P(CF..\ab and cd in parents) (when a is CF) = P(CFc\cd).
Finally, the risk for a further pregnancy could also be modified if the couple has a phenotypically normal child.
Although when counselling for a further pregnancy in obligate CF carriers the risk figures obtained for some genotypes are as good, or even better, than those obtained with microvillar enzyme (MVE) analysis alone, for most cases haplotype analysis should be combined with MVE in a Bayesian calculation. Haplotype data are entered as the 'prior probability' in the couple for a fetus with CF and MVE data as the 'conditional probability'.14 In the case of the sibs of a dead CF child, for whom no genetic material is available, and whose parents are negative for the AF508 mutation, their risk of carrying a CF mutation could be calculated using the linkage disequilibrium data in table 1 and Bayes's theorem.4 1920 The probability that a child with a normal phenotype and whose parents are obligate carriers is a carrier can be calculated as follows: P(C.d\ab and cd in parents) P(CF.C) + P(CFbd) P(CF.C) + P(CFb, ) + P(CFbd) -In the case that only one of the chromosomes (for example, haplotype a) in the phenotypically normal subject is at risk of carrying a CF mutation (that is, when a person is known to have inherited at least one normal chromosome from his/her parents), the probability that that person is a carrier is: P(C.d\ab and cd in parents) (when d is normal) = P(CF.\ab). P(CFfj) + P(CFf6) 2 x P(CFfj) + P(CFf,) = 050/054 = 0-92 and is modified from 2 in 3 to 1 in 1 1. Another example is shown in pedigree B. The sister of a dead CF patient has married into the general population. The couple are negative for the AF508 mutation, so she has not inherited AF508 from her mother, but she may still carry the CF mutation inherited from her father. The haplotype (a) that she has inherited from her father has a high risk (92 5%) of being a CF chromosome. On the other hand, the typing for her husband shows that he is homozygous for a haplotype (d) not present in CF chromosomes. Thus, although she has a high risk of carrying a CF mutation (1 in 1 1), the risk of the couple for CF is negligible. However, if her husband had an aa genotype, then the risk that the couple had a CF child would be: 1/4 x P(C n-AF\aa) x P(CF.\af)= 1/4 x 1/7 2 x 1/1-1 = 1/31.
LINKAGE DISEQUILIBRIUM
The degree of association between the DNA markers studied here and CF, as measured by Yule's association coefficient, is shown in table 4. Strong allelic association was detected with all RFLPs, but the highest degree of association with CF was found with pKM. 19/ScrfI, an allelic system situated 125 kb from the CF gene. The lower disequilibrium detected with markers which are closer to the CF gene (pKM.19/PstI and pMP6d-9/MspI) is probably the result of the variation in the allelic distribution among the normal chromosomes. pKM.19/ ScrfI also shows higher association with CF than markers not analysed here, but tested by others.3 This is true for several intragenic markers that are The data presented here are useful in our population, in which the majority of CF mutations, apart from the AF508 deletion, are uncommon. Data on the frequency of the major CF mutation in several south European populations, and the large mutation heterogeneity found in the non-AF508 mutant allele pool, suggest that RFLP and haplotype analysis may be the method of choice for genetic analysis in several circumstances. This is particularly true for all the Mediterranean countries, where it is estimated that only one-third of the 75 000 CF families from this region are expected to be fully informative for mutation analysis.'2 Therefore, for each population, data shouldbe obtained and analysed in order to provide useful risk modifications in the different situations. However, it is expected that mutations covering at least 5% of CF chromosomes each will be detected in some populations and that mutation tests could be developed that cover a large proportion of CF cases. If this is the case, linkage disequilibrium data will not be used in the way that has been shown here. However, if the number of mutations is very high, it still might be more feasible to use RFLPs for diagnostic purposes when mutation analysis for common mutations is negative and DNA is available from the index patient. 
